Kodiak Sciences Inc., a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018.
March 28, 2019
· 8 min read